Pangaea Biotech SL Product Pipeline Analysis, 2018 Update [Report Updated: 10082018] Prices from USD $750

10:42 EDT 7 Oct 2018 | BioPortfolio Reports

Summary


Pangaea Biotech SL Pangaea is a provider of molecular diagnostics and research and development services for cancer treatment. The company discovers and develops gene signatures and prognostic markers. Its services include molecular diagnosis, in vitro drug testing, clinical trials, biomarker discovery, drug development, dx platform validation, in licensing and out licensing services. Pangaea's molecular diagnosis services comprise gene amplification and translocation testing; mutation analysis in tumor tissue and blood, immunohistochemistry and gene expression programs. The company improves clinical development process through discovery of novel markers and validation in tumor samples and cell lines. It operates through pharmaceutical, diagnostics and biotech companies for anticancer drug development. Pangaea is headquartered in Barcelona, Spain.


This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


Scope:


The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company Pangaea Biotech SL

The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.


Reasons to Buy:


Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research Development strategies

Develop marketentry and market expansion strategies

Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio


Note: Some sections may be missing if data is unavailable for the company

More From BioPortfolio on "Pangaea Biotech SL Product Pipeline Analysis, 2018 Update [Report Updated: 10082018] Prices from USD $750"